M R D'Andrea

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Add Alzheimer's disease to the list of autoimmune diseases
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical, Research and Development, Drug Discovery, Spring House, PA 19477 0776, USA
    Med Hypotheses 64:458-63. 2005
  2. pmc Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation
    Ricardo Saban
    Department of Physiology, The University Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    BMC Physiol 7:4. 2007
  3. pmc Regulatory network of inflammation downstream of proteinase-activated receptors
    Ricardo Saban
    Department of Physiology, The University Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    BMC Physiol 7:3. 2007
  4. ncbi Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Spring House, Pennsylvania, 19477, USA
    Curr Pharm Des 12:677-84. 2006
  5. ncbi The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
    Michael R D'Andrea
    Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, D404, Spring House, PA 19477, USA
    Neurobiol Aging 25:675-83. 2004
  6. ncbi Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Spring House, PA 19477 0776, USA
    Brain Res 982:19-30. 2003
  7. ncbi The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Welsh and McKean Roads, Spring House, PA 19477 0776, USA
    Neurosci Lett 342:114-8. 2003
  8. ncbi Collagenase predigestion on paraffin sections enhances collagen immunohistochemical detection without distorting tissue morphology
    M R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug, Discovery, Spring House, PA 19477, USA
    Biotech Histochem 79:55-64. 2004
  9. doi PCNA indexing as a preclinical immunohistochemical biomarker for testicular toxicity
    M R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania, USA
    Biotech Histochem 83:211-20. 2008
  10. ncbi Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis
    Michael R D'Andrea
    Drug Discovery, D404, Johnson and Johnson Pharmaceutical Research and Development, L L C, P O Box 776, Welsh and McKean Roads, Spring House, PA 19477 0776, USA
    Mol Cancer Ther 4:1198-204. 2005

Collaborators

Detail Information

Publications20

  1. ncbi Add Alzheimer's disease to the list of autoimmune diseases
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical, Research and Development, Drug Discovery, Spring House, PA 19477 0776, USA
    Med Hypotheses 64:458-63. 2005
    ..Hence, these observations suggest autoimmunity-induced cell death in AD...
  2. pmc Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation
    Ricardo Saban
    Department of Physiology, The University Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    BMC Physiol 7:4. 2007
    ..We hypothesize that PARs may link mast cell-derived proteases to bladder inflammation and, therefore, play a fundamental role in the pathogenesis of cystitis...
  3. pmc Regulatory network of inflammation downstream of proteinase-activated receptors
    Ricardo Saban
    Department of Physiology, The University Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    BMC Physiol 7:3. 2007
    ..coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency...
  4. ncbi Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Spring House, Pennsylvania, 19477, USA
    Curr Pharm Des 12:677-84. 2006
    ....
  5. ncbi The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
    Michael R D'Andrea
    Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, D404, Spring House, PA 19477, USA
    Neurobiol Aging 25:675-83. 2004
    ..In summary, the data presented suggests that plaque associated microglial activation is typically subsequent to specific amyloid plaque formations in the AD brain...
  6. ncbi Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Spring House, PA 19477 0776, USA
    Brain Res 982:19-30. 2003
    ..Thus, the presence of +Ig-neurons in AD brains implies a critical link between the faulty BBB and neuronal death through an autoimmune mechanism...
  7. ncbi The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations
    Michael R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug Discovery, Welsh and McKean Roads, Spring House, PA 19477 0776, USA
    Neurosci Lett 342:114-8. 2003
    ..The obvious benefits of formic acid for increasing the sensitivity of amyloid plaque immunolabeling may artifactually emphasize plaques over amyloid-containing cells during analyses...
  8. ncbi Collagenase predigestion on paraffin sections enhances collagen immunohistochemical detection without distorting tissue morphology
    M R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Drug, Discovery, Spring House, PA 19477, USA
    Biotech Histochem 79:55-64. 2004
    ..This new use of collagenase for immunohistochemistry promotes increased collagen immunolabeling, is easy to use, is versatile, and allows preservation of tissue structure that provides maximal and accurate histological information...
  9. doi PCNA indexing as a preclinical immunohistochemical biomarker for testicular toxicity
    M R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania, USA
    Biotech Histochem 83:211-20. 2008
    ..The assay has potential utility as an in vivo biomarker for detecting early testicular toxicity of experimental compounds in preclinical development as well as for refining follow-up compounds with reduced testicular toxicity...
  10. ncbi Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis
    Michael R D'Andrea
    Drug Discovery, D404, Johnson and Johnson Pharmaceutical Research and Development, L L C, P O Box 776, Welsh and McKean Roads, Spring House, PA 19477 0776, USA
    Mol Cancer Ther 4:1198-204. 2005
    ..In addition to this specific application of this in vivo validation approach to those targets that use PLCgamma as a downstream signaling partner, these methods may also benefit other drug discovery targets...
  11. ncbi Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease
    M R D'Andrea
    The R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477, USA
    Histopathology 38:120-34. 2001
    ..We have investigated the possibility of a link between these two apparently conflicting observations...
  12. ncbi Altered vascular injury responses in mice deficient in protease-activated receptor-1
    W M Cheung
    Drug Discovery, The R W Johnson Pharmaceutical Research Institute, Spring House, PA 19477, USA
    Arterioscler Thromb Vasc Biol 19:3014-24. 1999
    ..These data suggest that PAR-1(-/-) may play a role in vascular injury responses in this mouse model via possible effects on extracellular matrix regulation...
  13. ncbi beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology
    H Y Wang
    R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477 0776, USA
    J Biol Chem 275:5626-32. 2000
    ....
  14. ncbi Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery
    B P Damiano
    Drug Discovery, The R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477, USA
    Thromb Haemost 81:808-14. 1999
    ..Possible functional consequences of this receptor upregulation and its role in the response to vascular injury remain to be determined...
  15. ncbi MAP-2 immunolabeling can distinguish diffuse from dense-core amyloid plaques in brains with Alzheimer's disease
    M R D'Andrea
    The R W Johnson Pharmaceutical Research Institute, Drug Discovery, Spring House, Pennsylvania 19477, USA
    Biotech Histochem 77:95-103. 2002
    ..Furthermore, this biochemical distinction indicates that dense-core and diffuse plaques are formed by different mechanisms...
  16. doi Simultaneous PCNA and TUNEL labeling for testicular toxicity evaluation suggests that detection of apoptosis may be more sensitive than proliferation
    M R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania, USA
    Biotech Histochem 85:195-204. 2010
    ....
  17. doi Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer's disease pathogenesis
    M R D'Andrea
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
    Biotech Histochem 85:133-47. 2010
    ....
  18. ncbi Abnormal patterns of microtubule-associated protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson's disease substantia nigra brain tissues
    M R D'Andrea
    The R W Johnson Pharmaceutical Research Institute, Welsh and McKean Roads, Spring House, PA 19477, USA
    Neurosci Lett 306:137-40. 2001
    ..These PD-associated alterations in MAP-2 morphology and distribution suggest that impaired neuronal transport may contribute to the progression of neuronal loss in the brains of PD patients...
  19. ncbi Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats
    P Andrade-Gordon
    Drug Discovery, The R W Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477 0776, USA
    J Pharmacol Exp Ther 298:34-42. 2001
    ..From these results, it is evident that a PAR-1 antagonist is not especially effective for treating platelet-dependent thrombosis; however, it could well be beneficial for treating restenosis attendant to arterial injury...
  20. doi Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease
    S M Belkowski
    Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477, USA
    Clin Exp Allergy 39:1179-86. 2009
    ..Previously, we demonstrated that chymase is able to cleave SLPI and that the cleaved portion, cSLPI, is a biomarker of chymase activity...